YARNO WENDY L — SEC insider filings
SEC reporting owner CIK 1181186. 36 insider filings on record with FilingPulse; latest filed 2026-09-17.
Transaction summary — filings shown
Covers all 36 filings on record, filed 2020-11-19 to 2026-09-17. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): none reported.
- Open-market sales (code S, non-derivative): none reported.
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 81.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | Director | 13 | — | — | 26 |
| INOVIO PHARMACEUTICALS, INC. (INO) | Director | 8 | — | — | 22 |
| Global Blood Therapeutics, Inc. (GBT) | Director | 3 | — | — | 16 |
| IDEAYA Biosciences, Inc. (IDYA) | Director | 6 | — | — | 6 |
| MyoKardia, Inc. (MYOK) | Director | 1 | — | — | 6 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Director | 5 | — | — | 5 |
Insider filings — YARNO WENDY L
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-09-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 302 · Option exercise (M): 302 (derivative) @ $0 | EDGAR |
| 2026-06-29 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 3,837 (derivative) @ $0 · Grant/award (A): 2,417 (derivative) @ $0 · Grant/award (A): 1,209 (derivative) @ $0 | EDGAR |
| 2026-06-18 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2026-06-16 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 2,954 · Option exercise (M): 2,954 (derivative) @ $0 | EDGAR |
| 2026-05-21 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Grant/award (A): 41,800 (derivative) @ $0 · Grant/award (A): 34,200 (derivative) @ $0 | EDGAR |
| 2025-06-26 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2025-06-17 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Grant/award (A): 67,546 (derivative) @ $0 | EDGAR |
| 2025-06-16 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 3,350 · Grant/award (A): 4,540 (derivative) @ $0 · Grant/award (A): 2,954 (derivative) @ $0 · Option exercise (M): 3,350 (derivative) @ $0 | EDGAR |
| 2025-05-21 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Option exercise (M): 2,167 · Option exercise (M): 2,167 (derivative) @ $0 | EDGAR |
| 2024-06-25 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 3,350 · Option exercise (M): 3,350 (derivative) @ $0 | EDGAR |
| 2024-06-14 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 5,000 (derivative) @ $0 · Grant/award (A): 3,350 (derivative) @ $0 | EDGAR |
| 2024-06-13 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Grant/award (A): 49,303 (derivative) @ $0 | EDGAR |
| 2024-05-31 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2024-05-22 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Grant/award (A): 2,917 (derivative) @ $0 · Grant/award (A): 2,167 (derivative) @ $0 | EDGAR |
| 2024-05-16 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Option exercise (M): 2,166 · Option exercise (M): 2,166 (derivative) @ $0 | EDGAR |
| 2024-03-05 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Grant/award (A): 25,000 (derivative) @ $0 | EDGAR |
| 2023-12-05 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 5,000 · Option exercise (M): 5,000 (derivative) @ $0 | EDGAR |
| 2023-06-26 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 5,000 (derivative) @ $0 · Grant/award (A): 3,350 (derivative) @ $0 | EDGAR |
| 2023-06-21 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Option exercise (M): 2,000 · Option exercise (M): 2,000 (derivative) @ $0 | EDGAR |
| 2023-06-09 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 16,200 (derivative) @ $0 | EDGAR |
| 2023-06-08 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Grant/award (A): 12,988 (derivative) @ $0 | EDGAR |
| 2023-05-16 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Option exercise (M): 19,000 · Option exercise (M): 19,000 (derivative) @ $0 · Grant/award (A): 35,000 (derivative) @ $0 · Grant/award (A): 26,000 (derivative) @ $0 | EDGAR |
| 2023-04-20 | 4 | IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | Grant/award (A): 74,823 (derivative) @ $0 | EDGAR |
| 2022-12-06 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2022-10-06 | 4 | Global Blood Therapeutics, Inc. (GBT) | Disposition to issuer (D): 11,437 · Disposition to issuer (D): 3,600 (derivative) · Disposition to issuer (D): 30,000 (derivative) · Disposition to issuer (D): 15,000 (derivative) · Disposition to issuer (D): 7,500 (derivative) · Disposition to issuer (D): 5,247 (derivative) · +2 more | EDGAR |
| 2022-07-01 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 7,000 (derivative) @ $0 · Grant/award (A): 2,000 (derivative) @ $0 | EDGAR |
| 2022-06-16 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 3,600 · Option exercise (M): 3,600 (derivative) @ $0 · Grant/award (A): 5,600 (derivative) @ $0 · Grant/award (A): 3,600 (derivative) @ $0 | EDGAR |
| 2022-06-10 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2022-05-17 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Option exercise (M): 18,000 · Option exercise (M): 18,000 (derivative) @ $0 · Grant/award (A): 19,000 (derivative) @ $0 · Grant/award (A): 28,000 (derivative) @ $0 | EDGAR |
| 2021-06-21 | 4 | Global Blood Therapeutics, Inc. (GBT) | Option exercise (M): 3,037 · Option exercise (M): 3,037 (derivative) @ $0 · Grant/award (A): 5,600 (derivative) @ $0 · Grant/award (A): 3,600 (derivative) @ $0 | EDGAR |
| 2021-06-17 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 5,000 (derivative) @ $0 | EDGAR |
| 2021-06-16 | 4 | IDEAYA Biosciences, Inc. (IDYA) | Grant/award (A): 11,000 (derivative) @ $0 | EDGAR |
| 2021-05-17 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Option exercise (M): 8,700 · Grant/award (A): 27,000 (derivative) @ $0 · Grant/award (A): 18,000 (derivative) @ $0 · Option exercise (M): 8,700 (derivative) @ $0 | EDGAR |
| 2020-12-07 | 4 | INOVIO PHARMACEUTICALS, INC. (INO) | Option exercise (M): 4,090 · Option exercise (M): 4,090 (derivative) @ $0 | EDGAR |
| 2020-11-23 | 4 | Tarsus Pharmaceuticals, Inc. (TARS) | Grant/award (A): 20,000 (derivative) @ $0 | EDGAR |
| 2020-11-19 | 4 | MyoKardia, Inc. (MYOK) | Code (U): 5,508 · Disposition to issuer (D): 22,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · Disposition to issuer (D): 11,000 (derivative) · Disposition to issuer (D): 6,600 (derivative) · Disposition to issuer (D): 3,000 (derivative) | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2020-11-18 and is expanding backward through EDGAR history; Forms 3 and 5 are covered live-forward since 2026-09-23 (no 3/5 history). Earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1181186 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. Get a free API key → · API docs